Oppenheimer analyst Trevor Allred raised the price target on Ligand Pharma (NASDAQ: LGND) to $190.00 (from $167.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE